Comments

Eisai Co Stock Price, Quotes and Forecasts

ESALFOTCPK
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers

Eisai Co (ESALF) Forecast

NewsEarningsEisai Co (ESALF) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
Edge Rankings

Eisai Co Stock Price, Quotes and Forecasts | OTC:ESALF | Benzinga

Explore Eisai Co stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ESALF.

Open-
Close-
Volume / Avg.0 / 1.36K
Day Range- - -
52 Wk Range22.51 - 45.46
Market Cap$7.33B
P/E Ratio23.43
Dividend Yield4.17%
ExchangeOTC
RSI
0
Short Interest-
Days to Cover999.99

Recent News

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.
Vandana Singh
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated the drug's benefits are too small to justify the cost for NHS use.
Vandana Singh
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards making the treatment available in the EU, where Alzheimer's affects 6.9 million people.
Vandana Singh
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Open-
Close-
Volume / Avg.0 / 1.36K
Day Range- - -
52 Wk Range22.51 - 45.46
Market Cap$7.33B
P/E Ratio23.43
Dividend Yield4.17%
ExchangeOTC
RSI
0
Short Interest-
Days to Cover999.99
About
Sector
Healthcare
Industry
N/A
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists ...
Show More

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
ESALF

FAQ

Q

How do I buy Eisai Co (ESALF) stock?

A

You can purchase shares of Eisai Co (OTCPK:ESALF) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Eisai Co (ESALF) competitors?

A

There are no as such competitors for Eisai Co.

Q

What is the forecast, or price target, for Eisai Co (ESALF) stock?

A

There is no analysis for Eisai Co to provide a consensus price target.

Q

What is the current price for Eisai Co (ESALF)?

A

The stock price for Eisai Co (OTCPK: ESALF) is $26 last updated May 14, 2025 at 9:44 AM EDT.

Q

Does Eisai Co (ESALF) pay a dividend?

A

There are no upcoming dividends for Eisai Co.

Q

When is Eisai Co (OTCPK:ESALF) reporting earnings?

A

Eisai Co does not have any upcoming earnings scheduled.

Q

Is Eisai Co (ESALF) going to split?

A

There is no upcoming split for Eisai Co.

Q

What sector and industry does Eisai Co (ESALF) operate in?

A

Eisai Co is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the OTCPK.

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved